Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective randomized controlled study of Epi-Rad90 ophthalmic system plus ranibizumab for subfoveal choroidal neovascularization due to wet age-related macular degeneration
2007-005798-75Phase 3Active
- Sponsor
- NeoVista
- Start
- Nov 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ranibizumab in exudative macular degeneration and choroidal neovascularization (CNV) (2 arms), sponsored by NeoVista. Primary endpoint: Visual acuity improvement ≥15 ETDRS letters. Started Nov 2007; status: active.
02
Drugs
ranibizumab
03
Conditions
exudative macular degenerationchoroidal neovascularization (CNV)
Beyond the preview
Go deeper on 2007-005798-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005798-75.